Dyne Therapeutics (NASDAQ:DYN) Releases Earnings Results, Misses Estimates By $0.15 EPS

Dyne Therapeutics (NASDAQ:DYN) announced its quarterly earnings data on Thursday. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.15), FiscalAI reports. During the same quarter last year, the firm earned ($0.76) EPS.

Dyne Therapeutics Trading Up 4.1%

Shares of NASDAQ DYN traded up $0.71 on Friday, reaching $18.07. 2,359,185 shares of the company traded hands, compared to its average volume of 2,812,952. The stock has a market capitalization of $3.37 billion, a PE ratio of -4.98 and a beta of 1.22. Dyne Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $27.31. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. The company has a 50 day moving average of $17.70 and a 200 day moving average of $19.33.

Insider Activity at Dyne Therapeutics

In related news, insider Douglas Kerr sold 3,745 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $24.35, for a total transaction of $91,190.75. Following the completion of the transaction, the insider owned 163,854 shares of the company’s stock, valued at approximately $3,989,844.90. This represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jason P. Rhodes sold 2,160,516 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the transaction, the director directly owned 428,946 shares of the company’s stock, valued at $10,723,650. This trade represents a 83.43% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,598,706 shares of company stock valued at $65,432,671 over the last three months. Insiders own 9.46% of the company’s stock.

Key Stories Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: The FDA is conducting a priority review of Dyne’s biologics license application for z-rostudirsen, its exon 51 Duchenne muscular dystrophy (DMD) candidate. The FDA’s target action date is January 21, 2027, providing a defined near-term regulatory catalyst. Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: Management said its cash runway extends into the second quarter of 2028, providing funding visibility for ongoing development. The company also reported progress in its DMD and DM1 programs ahead of planned 2027 milestones. Dyne Therapeutics Reports Q3 2026 Results; Advances DMD And DM1 Programs Ahead Of 2027 Milestones
• Neutral Sentiment: A valuation commentary raised the possibility that DYN is undervalued, citing its pipeline and the FDA priority review, but this is an opinion rather than a new company development. Is Dyne Therapeutics (DYN) Undervalued After Wider Losses And FDA Priority Review?
• Negative Sentiment: Third-quarter EPS was a loss of $1.06, wider than analysts’ expected $0.91 loss and the $0.76 loss a year earlier. Reports attributed the increased loss to higher research and development spending, highlighting rising development costs. Dyne Therapeutics Q3 Loss Widens On Higher R&D Costs; Cash Runway Extends Into Q2 2028

Analyst Ratings Changes

DYN has been the subject of several recent analyst reports. Oppenheimer cut shares of Dyne Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $40.00 to $15.00 in a research note on Wednesday, October 28th. Wall Street Zen downgraded Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Stifel Nicolaus set a $37.00 price target on Dyne Therapeutics in a research note on Wednesday, September 30th. Morgan Stanley reduced their price target on Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 9th. Finally, Robert W. Baird decreased their price objective on Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.29.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for serious muscle diseases. The company’s research is centered on conditions in which the delivery of therapeutic molecules to skeletal muscle and other tissues is a significant challenge.

Dyne uses its proprietary FORCE platform to design targeted therapies intended to improve the delivery of oligonucleotides into muscle cells. The platform incorporates antibodies that bind to the transferrin receptor, which can help transport genetic medicines across cell membranes and into muscle tissue.

Dyne’s pipeline includes DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.